Drug screens using the nematode Caenorhabditis elegans
Abstract
Since its inception as a model system, Caenorhabditis elegans has provided insight about the mechanism of action of drugs through genetic analyses. With the arrival of diverse drug-like small molecule libraries sometime later, the worm also became a platform for drug discovery that was previously inaccessible to academics. Here, the history of larger-scale drug screens using C. elegans is reviewed. The current approaches used to identify the targets and targeted pathways of the novel hits from these screens are also discussed. We focus on the development of small molecule tools for biological investigation, the discovery of novel candidate nematicides and anthelmintics, and touch on screens related to other areas of biology, including neurodegeneration. Finally, we draw attention to the fundamental aspects of C. elegans biology that lends itself to chemical genetic research. When combined with diverse small molecule libraries, the worm's tractability and genetic power make it an unparalleled whole-animal model system for early-stage drug discovery.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.